Section Arrow
Quote
EQ.NASDAQ
- Equillium
(Financial Status)
Quotes are at least 15-min delayed:2024/10/31 18:47 EDT
Last
 0.855
-0.525 (-38.04%)
Day High 
1.11 
Prev. Close
1.38 
1-M High
1.5 
Volume 
1.72M 
Bid
0.8401
Ask
0.8788
Day Low
0.8233 
Open
1.11 
1-M Low
0.81 
Market Cap 
48.89M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.2 
20-SMA 1.06 
50-SMA 0.97 
52-W High 3.25 
52-W Low 0.45 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.23/-0.78
Enterprise Value
49.27M
Balance Sheet
Book Value Per Share
0.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
15.76M
Operating Revenue Per Share
0.95
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed：2024/10/31 18:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.